L'adénome peut-il causer des problèmes cardiaques ?
Oui, l'excès de GH peut entraîner des cardiomyopathies et d'autres problèmes cardiovasculaires.
CardiomyopathiesProblèmes cardiovasculairesHormone de croissance
#3
Y a-t-il un risque accru de diabète ?
Oui, l'adénome à GH peut provoquer une résistance à l'insuline, augmentant le risque de diabète.
DiabèteRésistance à l'insulineAdénome hypophysaire
#4
Les troubles psychologiques sont-ils fréquents ?
Oui, des troubles comme l'anxiété et la dépression peuvent être des complications de l'adénome.
Troubles psychologiquesAnxiétéDépression
#5
Comment les complications sont-elles gérées ?
Les complications sont gérées par un suivi médical régulier et des traitements adaptés selon les symptômes.
Gestion des complicationsSuivi médicalTraitements
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les facteurs incluent des antécédents familiaux, des troubles endocriniens et des mutations génétiques.
Facteurs de risqueAntécédents familiauxMutations génétiques
#2
L'âge influence-t-il le risque d'adénome ?
Oui, le risque augmente généralement chez les adultes d'âge moyen, mais peut survenir à tout âge.
ÂgeRisqueAdénome hypophysaire
#3
Les hommes sont-ils plus à risque ?
Non, les hommes et les femmes sont également touchés par les adénomes à GH.
SexeRisqueAdénome hypophysaire
#4
Les maladies endocriniennes augmentent-elles le risque ?
Oui, des maladies comme la maladie de Cushing ou des syndromes génétiques peuvent augmenter le risque.
Maladies endocriniennesSyndromes génétiquesRisque
#5
Le mode de vie influence-t-il le risque d'adénome ?
Un mode de vie sain peut réduire le risque, mais des facteurs génétiques jouent un rôle plus important.
Mode de vieRisqueFacteurs génétiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Adénome hypophysaire à GH : Questions médicales les plus fréquentes",
"headline": "Adénome hypophysaire à GH : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Adénome hypophysaire à GH : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-26",
"dateModified": "2026-03-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Adénome hypophysaire à GH"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs de l'hypophyse",
"url": "https://questionsmedicales.fr/mesh/D010911",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de l'hypophyse",
"code": {
"@type": "MedicalCode",
"code": "D010911",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C19.700.734"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Adénome hypophysaire à GH",
"alternateName": "Growth Hormone-Secreting Pituitary Adenoma",
"code": {
"@type": "MedicalCode",
"code": "D049912",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yao Zhao",
"url": "https://questionsmedicales.fr/author/Yao%20Zhao",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China."
}
},
{
"@type": "Person",
"name": "Cheol Ryong Ku",
"url": "https://questionsmedicales.fr/author/Cheol%20Ryong%20Ku",
"affiliation": {
"@type": "Organization",
"name": "Pituitary Tumor Center, Severance Hospital, Seoul, Korea."
}
},
{
"@type": "Person",
"name": "Eun Jig Lee",
"url": "https://questionsmedicales.fr/author/Eun%20Jig%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Pituitary Tumor Center, Severance Hospital, Seoul, Korea."
}
},
{
"@type": "Person",
"name": "John D Carmichael",
"url": "https://questionsmedicales.fr/author/John%20D%20Carmichael",
"affiliation": {
"@type": "Organization",
"name": "USC Brain Tumor Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA."
}
},
{
"@type": "Person",
"name": "Gabriel Zada",
"url": "https://questionsmedicales.fr/author/Gabriel%20Zada",
"affiliation": {
"@type": "Organization",
"name": "USC Brain Tumor Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Effect and Potential Mechanism Analysis of Growth Hormone-Secreting Pituitary Adenomas on Thyroid Function.",
"datePublished": "2023-05-20",
"url": "https://questionsmedicales.fr/article/37217118",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.eprac.2023.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Uric acid levels correlate with disease activity in growth hormone-secreting pituitary adenoma patients.",
"datePublished": "2023-09-25",
"url": "https://questionsmedicales.fr/article/37818085",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1230852"
}
},
{
"@type": "ScholarlyArticle",
"name": "Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas.",
"datePublished": "2023-11-22",
"url": "https://questionsmedicales.fr/article/37870923",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1530/ERC-23-0196"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical characteristics and therapeutic outcomes of acromegalic patients with giant growth hormone-secreting pituitary adenomas: a single-center study of 67 cases.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37847430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11102-023-01356-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of growth hormone-secreting pituitary adenoma on limbic system and its correlation with cognitive impairment.",
"datePublished": "2024-08-08",
"url": "https://questionsmedicales.fr/article/39220995",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.heliyon.2024.e35867"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies endocriniennes",
"item": "https://questionsmedicales.fr/mesh/D004700"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies de l'hypophyse",
"item": "https://questionsmedicales.fr/mesh/D010900"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs de l'hypophyse",
"item": "https://questionsmedicales.fr/mesh/D010911"
},
{
"@type": "ListItem",
"position": 5,
"name": "Adénome hypophysaire à GH",
"item": "https://questionsmedicales.fr/mesh/D049912"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Adénome hypophysaire à GH - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Adénome hypophysaire à GH",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-04-28",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Adénome hypophysaire à GH",
"description": "Comment diagnostiquer un adénome à GH ?\nQuels tests sont utilisés pour évaluer la GH ?\nQuels symptômes indiquent un adénome à GH ?\nL'IRM est-elle nécessaire pour le diagnostic ?\nPeut-on diagnostiquer sans symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Adénome hypophysaire à GH",
"description": "Quels sont les signes de l'acromégalie ?\nComment l'adénome à GH affecte-t-il le métabolisme ?\nQuels troubles visuels peuvent survenir ?\nY a-t-il des symptômes psychologiques associés ?\nLes femmes sont-elles plus touchées par ces symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Adénome hypophysaire à GH",
"description": "Peut-on prévenir un adénome hypophysaire ?\nLes antécédents familiaux augmentent-ils le risque ?\nY a-t-il des habitudes de vie à adopter ?\nLes examens réguliers sont-ils importants ?\nLe stress influence-t-il le développement d'adénomes ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Adénome hypophysaire à GH",
"description": "Quels traitements sont disponibles pour l'adénome à GH ?\nLa chirurgie est-elle toujours nécessaire ?\nQuels médicaments sont utilisés pour traiter l'adénome ?\nLa radiothérapie est-elle efficace ?\nQuels sont les effets secondaires des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Adénome hypophysaire à GH",
"description": "Quelles complications peuvent survenir ?\nL'adénome peut-il causer des problèmes cardiaques ?\nY a-t-il un risque accru de diabète ?\nLes troubles psychologiques sont-ils fréquents ?\nComment les complications sont-elles gérées ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Adénome hypophysaire à GH",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque d'adénome ?\nLes hommes sont-ils plus à risque ?\nLes maladies endocriniennes augmentent-elles le risque ?\nLe mode de vie influence-t-il le risque d'adénome ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un adénome à GH ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins pour mesurer les niveaux de GH et d'IGF-1, ainsi que l'imagerie par résonance magnétique (IRM)."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la GH ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de stimulation et de suppression de la GH, ainsi que des dosages d'IGF-1, sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un adénome à GH ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent acromégalie, maux de tête, troubles visuels et fatigue excessive."
}
},
{
"@type": "Question",
"name": "L'IRM est-elle nécessaire pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IRM est essentielle pour visualiser la tumeur et évaluer sa taille et son impact sur les structures environnantes."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer sans symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains adénomes sont découverts accidentellement lors d'examens pour d'autres raisons."
}
},
{
"@type": "Question",
"name": "Quels sont les signes de l'acromégalie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent une croissance des mains, des pieds, des traits faciaux grossis et des douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Comment l'adénome à GH affecte-t-il le métabolisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il provoque une résistance à l'insuline, une augmentation de la masse musculaire et des troubles lipidiques."
}
},
{
"@type": "Question",
"name": "Quels troubles visuels peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles visuels comme la vision floue ou la perte de vision périphérique peuvent se produire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes psychologiques associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme l'anxiété, la dépression et des changements d'humeur peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus touchées par ces symptômes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'adénome à GH affecte les hommes et les femmes de manière égale, mais les symptômes peuvent varier."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir un adénome hypophysaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux augmentent-ils le risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de troubles endocriniens peuvent augmenter le risque d'adénomes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes de vie à adopter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain, avec une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Les examens réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des anomalies hormonales."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il le développement d'adénomes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut affecter la santé hormonale, mais son lien direct avec les adénomes n'est pas prouvé."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'adénome à GH ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la radiothérapie et des médicaments comme les analogues de la somatostatine."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, la décision dépend de la taille de la tumeur et des symptômes. Les médicaments peuvent suffire."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter l'adénome ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les analogues de la somatostatine et les antagonistes de la GH sont couramment prescrits."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut réduire la taille de la tumeur et contrôler la sécrétion de GH, mais elle prend du temps."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des nausées, des douleurs au site d'injection et des troubles hormonaux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles visuels, des maux de tête chroniques et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "L'adénome peut-il causer des problèmes cardiaques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'excès de GH peut entraîner des cardiomyopathies et d'autres problèmes cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'adénome à GH peut provoquer une résistance à l'insuline, augmentant le risque de diabète."
}
},
{
"@type": "Question",
"name": "Les troubles psychologiques sont-ils fréquents ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme l'anxiété et la dépression peuvent être des complications de l'adénome."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont gérées par un suivi médical régulier et des traitements adaptés selon les symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des troubles endocriniens et des mutations génétiques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'adénome ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement chez les adultes d'âge moyen, mais peut survenir à tout âge."
}
},
{
"@type": "Question",
"name": "Les hommes sont-ils plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les hommes et les femmes sont également touchés par les adénomes à GH."
}
},
{
"@type": "Question",
"name": "Les maladies endocriniennes augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme la maladie de Cushing ou des syndromes génétiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque d'adénome ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque, mais des facteurs génétiques jouent un rôle plus important."
}
}
]
}
]
}
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China.
National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Sate Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai, China.
National Center for Neurological Disorders, Shanghai, China.
Neurosurgical Institute of Fudan University, Fudan University, Shanghai, China.
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China. yezhaozj663812@126.com.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China. yezhaozj663812@126.com.
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; China Pituitary Disease Registry Center, Chinese Pituitary Adenoma Cooperative Group, Beijing, China.
Current studies on the effect of high growth hormone (GH)/insulin-like growth factor (IGF)-1 on thyroid function are inconsistent. The aim was to explore the effect and potential mechanism of high GH/...
This was a retrospective cross-sectional study. Demographic and clinical data of 351 patients with GHPA who were first admitted to Beijing Tiantan Hospital, Capital Medical University, from 2015 to 20...
GH was negatively correlated with total thyroxine (TT4), free thyroxine (FT4), and thyroid-stimulating hormone (TSH). IGF-1 was positively correlated with total triiodothyronine (TT3), free triiodothy...
The study emphasized the complex interaction between the GH and the thyroid axes in patients with GHPA and highlighted the potential effect of glycemic status and tumor volume on thyroid function....
Few studies reported the effects of growth hormone-secreting pituitary adenoma (GHPA) on uric acid (UA) metabolism and the relationship between growth hormone (GH)/insulin-like growth factor-1 (IGF-1)...
A longitudinal study of 424 GHPA patients presenting to Beijing Tiantan Hospital, Capital Medical University between January 2015 and January 2023 was conducted. Spearman's correlation tests were perf...
At baseline, male patients, the lower the age, the higher the IGF-1 and body mass index (BMI), and the higher the UA levels. IGF-1 was significantly associated with UA after controlling for sex, age, ...
In patients with GHPA, UA levels are associated with disease activity. Changes in UA levels should be taken into account in the comprehensive treatment of GHPA, patients presenting with HUA should be ...
Cytotoxic T lymphocyte-associated protein 4 (CTLA4), a negative regulator typically expressed on the surface of T lymphocytes, is targeted by immunotherapy in patients with an ever-expanding spectrum ...
Acromegalic patients with giant growth hormone-secreting pituitary adenomas (GHPAs) (≥ 40 mm) are relatively rare, and their clinical characteristics and treatment outcome data are limited. This study...
Sixty-seven acromegalic patients with giant GHPAs and 67 patients with macro GHPAs (10-39 mm), matched for age and gender from the same hospital during the same period, were retrospectively recruited....
Enlargement of the extremities and facial features were the most common symptoms in most patients (92.5%). Compared with the macroadenoma group, more frequent visual impairment (86.6% vs. 25.4%, P < 0...
With aggressive multimodal therapy, the biochemical remission rate of acromegalic patients with giant GHPAs is comparable to that of patients with macro adenoma. However, postoperative complications a...
To assess the quantitative gray matter volume of the limbic system in growth hormone-secreting pituitary adenoma (GHPAs) patients and its correlation to cognitive function....
91 right-handed patients with pituitary adenomas were retrospectively included from the First Affiliated Hospital of Sun Yat-sen University -48 with GHPAs and 43 with non-functioning pituitary adenoma...
Compared to NFPAs patients, GHPAs patients had higher gray matter volume (758,285 vs 674,610 mm³, p < 0.001). No significant volumetric differences in both sides of limbic system gray matter while the...
Patients with GHPAs show a relative decrease in limbic gray matter volume, especially in the hippocampus and limbic cortex of the dominant hemisphere, which is associated with mild cognitive impairmen...
A 40-year-old man presented with acromegaly, reduction of visual acuity and visual field, and elevated blood sugar. Imaging examinations demonstrated a large sellar adenoma with suprasellar extension ...
Acromegaly is a rare endocrine disorder characterized by excessive growth hormone (GH) secretion, usually due to a pituitary adenoma. This condition leads to progressive somatic disfigurement, includi...
The coexistence of growth hormone-secreting pituitary adenoma (GHPA) and Graves' disease (GD) is rare. This study aimed to investigate the relationship between growth hormone (GH)/insulin-like growth ...
Eleven patients with GHPA combined with GD during 2015-2022 were collected by searching the medical record system of Beijing Tiantan Hospital, Capital Medical University. Changes in GH/IGF-1 levels an...
After the application of ATD, with the decrease of thyroid hormone levels, GH/IGF-1 levels also decreased gradually. In patients without ATD application, after surgery or SSA treatment, thyroid hormon...
Hyperthyroidism due to GD promotes the secretion of GH/IGF-1, and when thyroid hormone levels were decreased by the use of ATD, GH and IGF-1 levels were also decreased, suggesting that thyroid hormone...
Growth hormone (GH)-secreting pituitary adenoma is a severe endocrine disease. Surgery is the currently recommended primary therapy for patients with GH-secreting tumours. However, non-surgical therap...
To assess the effects of surgical and non-surgical interventions for primary and salvage treatment of GH-secreting pituitary adenomas in adults....
We searched CENTRAL, MEDLINE, WHO ICTRP, and ClinicalTrials.gov. The date of the last search of all databases was 1 August 2022. We did not apply any language restrictions....
Randomised controlled trials (RCTs) and quasi-RCTs of more than 12 weeks' duration, reporting on surgical, pharmacological, radiation, and combination interventions for GH-secreting pituitary adenomas...
Two review authors independently screened titles and abstracts for relevance, screened for inclusion, completed data extraction, and performed a risk of bias assessment. We assessed studies for overal...
We included eight RCTs that evaluated 445 adults with GH-secreting pituitary adenomas. Four studies reported that they included participants with macroadenomas, one study included a small number of pa...
Within the context of GH-secreting pituitary adenomas, patient-relevant outcomes, such as disease-related complications, adverse events and disease recurrence were not, or only sparsely, reported. Whe...
Transsphenoidal surgery (TSS) is considered the treatment of choice in most patients with growth hormone (GH)-secreting pituitary adenomas. Several preoperative factors have been studied to predict po...
A retrospective analysis of consecutive patients with GH-secreting pituitary adenomas that underwent TSS in our institution from 2000-2015 who fulfilled prespecified criteria were included. Logistic r...
Sixty-eight patients were included, with a mean follow-up time of 87 months. Twenty (29%) patients had tumors with a Knosp grade ≥ 3A. Gross-total resection (GTR) was achieved in 43 (63%) patients. Th...
A novel, simple, easy-to-use scoring system was created to identify patients with the highest chances of long-term biochemical remission following TSS. This scale should be prospectively validated in ...